EWM
ESPR icon

Edge Wealth Management’s Esperion Therapeutics ESPR Stock Holding History

Edge Wealth Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-469
Closed -$18K – 624
2018
Q2 		$18K Buy
+469
New +$23.7K ﹤0.01% 361

Other funds holding ESPR

BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Edge Wealth Management's ESPR Position: Q3 2018 in Review

Edge Wealth Management sold out of Esperion Therapeutics (ESPR) in Q3 2018, closing a stake of 469 shares — an estimated $18K sold.

Edge Wealth Management first reported a position in ESPR in Q2 2018 and held it in 1 quarter. The position peaked at $18K in Q2 2018. 155 funds tracked by Wall St. Rank hold ESPR as of Q3 2018.

  • Edge Wealth Management reported no remaining Esperion Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Edge Wealth Management sold 469 Esperion Therapeutics shares in Q3 2018, an estimated $18K.
  • Edge Wealth Management first reported a position in Esperion Therapeutics in Q2 2018 and held it in 1 quarter.
  • Edge Wealth Management's Esperion Therapeutics position peaked at $18K in Q2 2018.
  • 155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2018.

Based on Edge Wealth Management's 13F filing for Q3 2018, filed 22 Oct 2018.